**Vaxcyte, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update**

Vaxcyte, Inc., a clinical-stage vaccine company, reported a net loss of $766.6 million for the year ended December 31, 2025, compared to a net loss of $463.9 million for the previous fiscal year. The increased loss was primarily driven by a significant rise in research and development expenses, which totaled $794.3 million in 2025, up from $476.6 million in 2024. General and administrative expenses also increased to $129.4 million from $92.9 million in the prior year. These increases were partially offset by a rise in other income, net, which reached $157.0 million, compared to $105.6 million in 2024, primarily due to foreign currency gains and higher interest income.

The company's research and development expenses were primarily focused on advancing its pneumococcal conjugate vaccine (PCV) candidates, VAX-31 and VAX-24, through clinical trials. A significant portion of the R&D expenditure was allocated to product manufacturing costs, which increased to $403.2 million in 2025 from $173.3 million in 2024, reflecting increased manufacturing activities to support clinical trials and potential future commercial launches. Clinical trial-related expenses also increased to $83.8 million from $66.5 million in the same period. Internal personnel-related expenses within research and development also rose to $193.6 million, up from $127.1 million, due to increased headcount.

Key operational developments included the initiation of Phase 3 trials for VAX-31 in adults, specifically the OPUS-1, OPUS-2, and OPUS-3 studies. The FDA also expanded the Breakthrough Therapy Designation for VAX-31 to include the prevention of pneumonia caused by Streptococcus pneumoniae. In the pediatric indication, Vaxcyte completed enrollment in the VAX-31 infant Phase 2 dose-finding study. The company also announced positive interim and final data from the VAX-24 infant Phase 2 dose-finding study. In addition, Vaxcyte is advancing VAX-A1, a vaccine candidate designed to prevent disease caused by Group A Streptococcus, into the clinic, with plans to initiate a Phase 1 adult study in 2026.

Looking ahead, Vaxcyte anticipates that its existing cash, cash equivalents, and investments, which totaled $2.44 billion as of December 31, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the filing date of the annual report. The company expects to continue to incur significant expenses as it progresses its vaccine candidates through clinical development, scales up manufacturing activities, and expands its research and development efforts. Vaxcyte plans to finance its future cash needs through a combination of public and private equity offerings, debt financings, third-party funding, and strategic collaborations.

About Vaxcyte, Inc.

Vaxcyte, Inc. is a vaccine innovation company developing broad-spectrum conjugate and protein vaccines targeting bacterial infectious diseases. Utilizing advanced synthetic chemistry and cell-free protein synthesis platforms, it focuses on pneumococcal, Group A Streptococcus, periodontitis, and shigellosis vaccines for adult and pediatric markets. Its core value lies in creating highly immunogenic, scalable, and next-generation vaccines to address unmet medical needs and improve global health.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.